G01N33/56911

Bacterial biofilms and cancer

Compositions for the treatment of colorectal cancer target bacterial biofilms in the gastrointestinal tract. Methods of treatment include one or more agents which target bacteria and the bacterial biofilms.

IMMUNO-BASED BOTULINUM TOXIN SEROTYPE A ACTIVITY ASSAYS

The present specification discloses SNAP-25 compositions, methods of making α-SNAP-25 antibodies that bind an epitope comprising a carboxyl-terminus at the P.sub.1 residue from the BoNT/A cleavage site scissile bond from a SNAP-25 cleavage product, α-SNAP-25 antibodies that bind an epitope comprising a carboxyl-terminus at the P.sub.1 residue from the BoNT/A cleavage site scissile bond from a SNAP-25 cleavage product, methods of detecting BoNT/A activity, and methods of detecting neutralizing α-BoNT/A antibodies.

NOVEL RECOMBINANT FACTOR C AND METHOD FOR PRODUCING THE SAME, AND METHOD FOR MEASURING ENDOTOXIN

A horseshoe crab Factor C protein having activity of Factor C, wherein the horseshoe crab is selected from Tachypleus tridentatus, Limulus polyphemus, and Carcinoscorpius rotundicauda, and wherein the horseshoe crab Factor C protein is produced through being recombinantly expressed from a Chinese Hamster Ovary (CHO) DG44 cell or HEK cell.

METHOD FOR LATERAL FLOW IMMUNOASSAY
20220146522 · 2022-05-12 · ·

The present disclosure relates to a novel method for lateral flow immunoassay (LFIA) by utilizing plasmonic enhancement strategy. More specifically, the present disclosure provides a plasmonic enhanced lateral flow sensor (pLFS) concept by introducing a liposome-based amplification of the colorimetric signals on the lateral flow platform for ultrasensitive detection of pathogens.

HIGH-SENSITIVITY ASSAY

Disclosed herein are biological assays, screening formats, detection devices, and related methods of use. More specifically, disclosed herein are assay formats, microarrays, devices, methods of making the same, and methods of screening, detecting a target analyte, and methods of diagnosing an individual with a disease or condition when a target analyte associated with the disease or condition is detected.

Anti-ETEC adhesin protein antibodies and methods of use

The invention provides anti-ETEC adhesin protein antibodies and methods of using the same.

POLYPEPTIDES OF FUSOBACTERIUM AND METHODS OF USE
20230256073 · 2023-08-17 ·

The present invention provides isolated polypeptides isolatable from a Fusobacterium spp. Also provided by the present invention are compositions that include one or more of the polypeptides, and methods for making and methods for using the polypeptides.

ENDOTOXIN DETECTION

Provided herein are methods and compositions for overcoming Low Endotoxin Recovery (LER) and unmasking endotoxins. The compositions and methods provided herein may be used to prepare samples such as drug products for endotoxin testing.

IN-VITRO POTENCY ASSAY FOR PROTEIN-BASED MENINGOCOCCAL VACCINES

The invention uses ELISA or similar assays for analysing a meningococcal vaccine. The assay uses antibodies which bind to meningococcal proteins within the vaccine, and in particular monoclonal antibodies which are bactericidal for meningococcus and/or which recognise conformational epitopes within the meningococcal proteins. By performing the assay on a series of dilutions of a test vaccine, and by comparing the results with those obtained using a reference vaccine of known potency, it is possible to determine the relative potency of the test vaccine. This value can be used as a parameter for determining whether a manufactured batch of a vaccine is suitable for release to the public, or whether it has experienced a production failure and so should not be used.

RAPID DETECTION OF ANALYTES

Rapid detection of analytes including, for example, systems, kits, and methods for growth, isolation, and/or monitoring of analytes are generally disclosed. In some embodiments, the systems and methods described herein are generally directed to the capture and/or concentrating of a target species (e.g., analyte) to be detected and/or monitored. In some embodiments, the materials, systems, and methods described herein may be used to create luminescent signals in response to the presence of selected analytes such as bacteria, viruses, and parasites. In some cases, the target analyte is a pathogenic bacteria, a pathogenic virus, a pathogenic parasite, or toxin.